Robert Barrow
Chief Executive Officer at Definium Therapeutics Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Definium Therapeutics Inc., 3 years.
Definium Therapeutics Inc.
Director · Chief Executive Officer
Chief executive roles
Definium Therapeutics Inc.
· Chief Executive Officer
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 12, 2026 | Definium Therapeutics Inc. | Grant or award | +375,000 | — | — |
| Jun 25, 2026 | Definium Therapeutics Inc. | Open-market sale | −29,208 | $45.03 | $1,315,236 |
| Jun 22, 2026 | Definium Therapeutics Inc. | Grant or award | +375,000 | — | — |
| Mar 25, 2026 | Definium Therapeutics Inc. | Open-market sale | −24,431 | $18.47 | $451,241 |
| Feb 3, 2026 | Definium Therapeutics Inc. | Grant or award | +320,000 | — | — |
| Dec 26, 2025 | Definium Therapeutics Inc. | Open-market sale | −25,791 | $13.15 | $339,152 |
| Sep 25, 2025 | Definium Therapeutics Inc. | Open-market sale | −25,797 | $9.77 | $252,037 |
| Jun 25, 2025 | Definium Therapeutics Inc. | Open-market sale | −26,491 | $6.80 | $180,139 |
| Mar 25, 2025 | Definium Therapeutics Inc. | Open-market sale | −21,208 | $6.74 | $142,942 |
| Mar 12, 2025 | Definium Therapeutics Inc. | Grant or award | +350,000 | — | — |
| Dec 26, 2024 | Definium Therapeutics Inc. | Open-market sale | −19,106 | $7.43 | $141,958 |
| Sep 25, 2024 | Definium Therapeutics Inc. | Open-market sale | −19,771 | $5.98 | $118,231 |
| Aug 20, 2024 | Definium Therapeutics Inc. | Open-market purchase | +500 | $6.12 | $3,060 |
| Aug 19, 2024 | Definium Therapeutics Inc. | Open-market purchase | +500 | $6.31 | $3,155 |
| Jun 25, 2024 | Definium Therapeutics Inc. | Open-market sale | −15,659 | $7.22 | $113,058 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.